A thrombotic stroke is a type of stroke caused by the formation of a blood clot (thrombus) in a cerebral vessel, a blood vessel that supplies oxygen-rich blood to the brain. The clot could be formed by a blood vessel narrowing due to atherosclerosis (hardening of the arteries) or a tear in the inner lining of the vessel wall. A thrombotic stroke is the most common type of stroke, accounting for approximately 85 percent of all strokes. It can occur in both men and women at any age, but it is more common in people over the age of 65. Thrombotic stroke is primarily caused by a buildup of extremely fatty substances known as plaque in the walls of the arteries leading to the brain. Over time, the plaque can narrow the artery and reduce the flow of blood to the brain. A tear in the artery wall can also lead to a thrombus, and low blood flow may accelerate clot formation. When these conditions occur, a thrombus can form and block or reduce the flow of blood to the brain, resulting in a thrombotic stroke. In addition to plaque buildup, certain illnesses and medications can make people more likely to experience a thrombotic stroke, including atrial fibrillation, heart valve disorders, high cholesterol, diabetes, high blood pressure, and some hormone treatments. The symptoms of a thrombotic stroke depend on the size and location of the clot-causing tissue damage. Common symptoms include sudden weakness and numbness of the face, arm, and/or leg on one side of the body, trouble speaking or understanding, loss of vision, difficulty walking, dizziness, and difficulty with balance and coordination. These symptoms can start suddenly, and can worsen quickly within a few minutes. Medical attention should be sought immediately to reduce the risk of permanent impairment or death. Treatment of thrombotictroke involves
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States